Holen Sie sich die Stockscreener-App
18.75
2.25%
-0.355
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$19.11
Offen:
$18.77
24-Stunden-Volumen:
43,807
Relative Volume:
0.02
Marktkapitalisierung:
$1.31B
Einnahmen:
$1.03B
Nettoeinkommen (Verlust:
$-94.55M
KGV:
-13.38
EPS:
-1.4012
Netto-Cashflow:
$-3.64M
1W Leistung:
-8.57%
1M Leistung:
-18.11%
6M Leistung:
-14.63%
1J Leistung:
+51.01%
1-Tages-Spanne:
$18.56
$18.85
1-Wochen-Bereich:
$18.56
$20.62
52-Wochen-Spanne:
$11.46
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
18.80 | 1.38B | 1.03B | -94.55M | -3.64M | -1.4012 |
ABT
Abbott Laboratories
|
104.80 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.11 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
274.42 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.08 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.60 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Truist | Hold → Buy |
| 2026-03-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Hochstufung | Lake Street | Hold → Buy |
| 2026-02-20 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now - Yahoo Finance
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
(TNDM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look at Tandem Diabetes Care Inc (TNDM) After 3.4% Decline -- GF Value $24.05 vs Price $20.56 - GuruFocus
Tandem Diabetes Care stock gains after recent rally in diabetes tech - ad-hoc-news.de
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Tandem Diabetes Care (TNDM) Edges Higher to $21.49, Holding Above Key SupportGrowth ETF - vinanet.vn
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Sahm
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat? - TradingView
TNDM Initiated Coverage On by William Blair -- Rating Set to Out - gurufocus.com
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics - Benzinga
William Blair initiates Tandem Diabetes stock with outperform rating By Investing.com - Investing.com Nigeria
Tandem Diabetes (TNDM) Q2 2026 Earnings Call Transcript - AOL.com
How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors - simplywall.st
Tandem (TNDM) Earnings Brief: Profit Per Share Clears Its Benchmark in the Current Update; Price Action: Shares Finish 6.63% Up at the CloseEarnings Season Preview - Vinanet
Tandem Diabetes Care CFO Leigh Vosseller Reports RSU Vesting Transactions on August 15, 2026 - Kalkine Media
Tandem Diabetes Care CEO John F. Sheridan Reports August 2026 RSU Vesting and Tax Withholding Details - Kalkine Media
Tandem Diabetes Care | 4: Statement of changes in beneficial ownership of securities-Officer Sheridan John F - Moomoo
Tandem Diabetes Care | 4: Statement of changes in beneficial ownership of securities-Officer Morrison Susan - Moomoo
Tandem Diabetes (TNDM) CFO vests RSUs as shares withheld for tax - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) exec nets 475 shares after RSU vesting - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) CEO vests 15,916 RSUs as shares withheld for tax - Stock Titan
Tandem Diabetes Care | 4: Statement of changes in beneficial ownership of securities-Officer Kyrillos Jean-Claude - Moomoo
Tandem Diabetes (NASDAQ: TNDM) CSO vests 3,014 RSUs, 1,618 withheld - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) CLO RSUs vest, with shares withheld for taxes - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) CTO withholds 1,277 shares to cover RSU taxes - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) holder to sell 131 RSU shares - Stock Titan
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) (Q2 2026) Earnings Call Highligh - GuruFocus
Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Renaissance Technologies LLC Purchases New Position in Tandem Diabetes Care, Inc. $TNDM - MarketBeat
Tandem Diabetes Care (NASDAQ:TNDM) Shares Cross Above 200-Day Moving AverageTime to Sell? - marketbeat.com
5 Must-Read Analyst Questions From Tandem Diabetes’s Q2 Earnings Call - Yahoo Finance
TNDM|Tandem Diabetes Care Inc|Price:22.617|Chg%:-0.513 - TradingKey
(TNDM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up - The Globe and Mail
Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Analyzing 25% Potential Upside with No Sell Ratings - DirectorsTalk Interviews
Tandem Diabetes Care Inc (TNDM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today - Yahoo Finance
TNDM Q2 Deep Dive: Pharmacy Channel Gains and Pipeline Execution Amid Margin Recovery - Yahoo Finance
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Record Q2 Sales And PayGo Momentum - finance.yahoo.com
Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results - Yahoo Finance
TNDM Maintained by Citigroup -- Price Target Raised to $21.00 - GuruFocus
Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Deutsche Bank Adjusts Tandem Diabetes Care PT to $18 From $15.50, Maintains Hold Rating - Moomoo
Oppenheimer reiterates Tandem Diabetes stock rating on pharmacy gains By Investing.com - Investing.com South Africa
TNDM Maintained by RBC Capital -- Price Target Lowered to $26 - GuruFocus
Tandem Diabetes Care Is Maintained at Outperform by RBC Capital - Moomoo
Tandem Diabetes Care, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNDM) 2026-08-07 - Seeking Alpha
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):